HK1221916A1 - 使用阿曲生坦用於改善脂质概况的方法 - Google Patents

使用阿曲生坦用於改善脂质概况的方法 Download PDF

Info

Publication number
HK1221916A1
HK1221916A1 HK16110230.1A HK16110230A HK1221916A1 HK 1221916 A1 HK1221916 A1 HK 1221916A1 HK 16110230 A HK16110230 A HK 16110230A HK 1221916 A1 HK1221916 A1 HK 1221916A1
Authority
HK
Hong Kong
Prior art keywords
methods
atrasentan
cholesterol
subject
lipid profiles
Prior art date
Application number
HK16110230.1A
Other languages
English (en)
Chinese (zh)
Inventor
Blas COLL CRESPO
Dennis ANDRESS
Peter J. BRENNAN
James C. Stolzenbach
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of HK1221916A1 publication Critical patent/HK1221916A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16110230.1A 2013-04-30 2014-04-30 使用阿曲生坦用於改善脂质概况的方法 HK1221916A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361817645P 2013-04-30 2013-04-30
US61/817,645 2013-04-30
US201361824199P 2013-05-16 2013-05-16
US61/824,199 2013-05-16
PCT/US2014/036152 WO2014179453A1 (en) 2013-04-30 2014-04-30 Methods for improving lipid profiles using atrasentan

Publications (1)

Publication Number Publication Date
HK1221916A1 true HK1221916A1 (zh) 2017-06-16

Family

ID=50928265

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110230.1A HK1221916A1 (zh) 2013-04-30 2014-04-30 使用阿曲生坦用於改善脂质概况的方法

Country Status (13)

Country Link
US (1) US9855245B2 (https=)
EP (1) EP2991680A1 (https=)
JP (1) JP2016521279A (https=)
KR (1) KR20160003128A (https=)
CN (1) CN105246512A (https=)
AU (1) AU2014259961A1 (https=)
BR (1) BR112015027631A2 (https=)
CA (1) CA2909871A1 (https=)
HK (1) HK1221916A1 (https=)
MX (1) MX2015015036A (https=)
RU (1) RU2015151175A (https=)
SG (1) SG11201508960SA (https=)
WO (1) WO2014179453A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
CN118852054A (zh) 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
CA3161516A1 (en) 2019-12-17 2021-06-24 Philip Thomas FROHLICH Methods of treating iga nephropathy with atrasentan
IL297208A (en) * 2020-04-10 2022-12-01 Chinook Therapeutics Inc Treatment methods for diabetic kidney disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (https=) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
WO2006034094A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
EP1802610A1 (en) 2004-09-17 2007-07-04 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
US9051301B2 (en) 2004-09-17 2015-06-09 Abbvie Inc. Crystalline form of a drug
US20060135596A1 (en) 2004-09-17 2006-06-22 Zhang Geoff G Amorphous form of a drug
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
US20080132710A1 (en) 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
CN101822837A (zh) * 2010-02-02 2010-09-08 王丽燕 包含艾力沙坦酯盐的药物组合物
CN105324395A (zh) 2013-03-08 2016-02-10 艾伯维公司 治疗急性肾损伤的方法

Also Published As

Publication number Publication date
MX2015015036A (es) 2016-02-09
BR112015027631A2 (pt) 2017-08-22
JP2016521279A (ja) 2016-07-21
AU2014259961A1 (en) 2015-11-05
SG11201508960SA (en) 2015-11-27
CA2909871A1 (en) 2014-11-06
EP2991680A1 (en) 2016-03-09
CN105246512A (zh) 2016-01-13
US9855245B2 (en) 2018-01-02
US20160074363A1 (en) 2016-03-17
WO2014179453A1 (en) 2014-11-06
KR20160003128A (ko) 2016-01-08
RU2015151175A (ru) 2017-06-07

Similar Documents

Publication Publication Date Title
HK1221916A1 (zh) 使用阿曲生坦用於改善脂质概况的方法
WO2014004993A3 (en) Methods of reducing ldl-p
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
HK1197159A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
WO2014062720A3 (en) Methods of treating cancer
BR112015020209A2 (pt) uso de linagliptina em terapia antidiabética de proteção cardíaca e renal
WO2012062925A3 (en) Compounds and methods for treating pain
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
WO2012174487A8 (en) Bromodomain inhibitors and uses thereof
IN2015DN03219A (https=)
WO2012135671A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2013006335A3 (en) Methods and compositions useful for treating fitzpatrick type iv, v or vi skin
WO2013117744A3 (en) Methods of treating fibrosis
WO2012142413A3 (en) Nitrite compositions and uses thereof
WO2015003122A3 (en) Regulation of glucose metabolism using anti-cgrp antibodies
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
MX369122B (es) Suplementos herbales y métodos para utilizar los mismos.
NZ616048A (en) Administration of iloprost as aerosol bolus
WO2013155528A3 (en) Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels
BR112016007238A2 (pt) tienouracilcarboxamidas cíclicas e sua utilização
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
MX339834B (es) Regimen terapeutico y metodos para tratar o mejorar trastornos visuales asociados a deficiencia endogena de retinoide.
HK1225972A1 (zh) 利用拉喹莫德来延缓亨廷顿氏病的进展
WO2014064609A3 (en) HERBAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF TNF-α MEDIATED DISEASES